Dermatology’s prior-authorization problem concentrates in one pattern: step therapy. Before a payer will cover the biologic the dermatologist prescribed, the patient must document failure of older, cheaper agents — methotrexate, phototherapy, conventional immunosuppressants. The gating is structural, the documentation requirements vary by payer, and a meaningful share of denial letters don’t even tell you what the payer wanted.
The numbers in dermatology
A 2020 study in the Journal of the American Academy of Dermatology (Jew et al., n reported as real-world claims) measured the delay directly:
- 12 days median time from prescription to biologic approval.
- IQR of 5.5–23 days — a quarter of patients waited three weeks or more.
A 2026 analysis by Ershadi, Barbieri and colleagues in JAAD (94(3):1031–1033) examined the denial letters themselves and found structural opacity on top of the delay:
- 41% of denial letters omit step-therapy requirements or covered alternatives, making appeals harder to mount.
- 75% of denial letters don’t name a decision-maker, blocking the peer-to-peer path.
These sit on top of the universal burden: 39 authorizations per physician per week, roughly 13 hours lost to them, and 93% of physicians reporting that PA delays care (AMA 2024).
Why dermatology is different
- Step therapy is structural. Psoriasis, atopic dermatitis, and hidradenitis suppurativa all have approved biologics, but payers require documented failure of cheaper agents first — independent of whether those agents are appropriate for the patient.
- Per-payer documentation. Each payer has its own shape for what “documented failure” looks like: duration on prior agents, severity thresholds, phototherapy trial requirements. The same patient history has to be reassembled in each payer’s format.
- Opaque denial letters. If 41% of denial letters omit which step-therapy alternative was expected, the practice has to call to find out — adding another loop before the appeal can even begin.
- Recurring re-authorizations. Biologic maintenance therapy must be re-authorized on each payer’s schedule; a lapsed auth interrupts treatment.
What it costs
The clinical cost is clear-to-skin time: moderate-to-severe psoriasis or atopic dermatitis that could be controlled isn’t, while the step-therapy clock runs. The operational cost is staff hours — assembling prior-treatment histories, decoding opaque denial letters, mounting appeals without a named decision-maker, and then doing it again at every re-authorization. At roughly $10.81 per manually processed authorization (CAQH 2023), a biologic practice with high volume runs this overhead on every patient and every re-auth cycle.
How to cut the wait
The dermatology authorization packet is structured documentation: prior agents, duration, outcomes, disease-activity scores. Software should assemble it, not a technician decoding a fax. Artificer Health:
- Builds the step-therapy record from the patient’s chart — prior agents tried, trial duration, failure documentation, and the clinical severity data each payer asks for.
- Matches it to the payer’s criteria so the first submission satisfies that payer’s specific step-therapy requirements, reducing the back-and-forth that follows opaque denials.
- Tracks re-authorizations so biologic maintenance therapy never lapses for an administrative reason.
The goal: a 12-day median approval measured in hours instead, with fewer mystery denial letters and maintenance therapy that stays uninterrupted.
Sources: Jew OS et al., J Am Acad Dermatol 2020;83(6):1674–1680 (PMID 32622138, median 12-day approval, IQR 5.5–23, complex dermatologic conditions); Ershadi S, Barbieri JS et al., J Am Acad Dermatol 2026;94(3):1031–1033 (PMID 41192514, denial-letter transparency); AMA 2024 Prior Authorization Physician Survey; CAQH 2023 Index.